Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival

Leukemia and Lymphoma

Volumn 50, Issue 9, 2009, Pages 1512-1518

  Paul, Esbjörn ^a,b   Uggla, Bertil ^b,c   Deneberg, Stefan ^a,b   Bengtzen, Sofia ^a,b   Hermansson, Monica ^d   Dahlman, Ingrid ^a,b   Rosenquist, Richard ^d   Wiman, Klas G ^b,e   Nahi, Hareth ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e Karolinska Krankenhaus   (Sweden)

Author keywords

drug resistance; FLT3; NPM 1; overall survival; PRIMA 1; TP53

Indexed keywords

CD135 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; NUCLEOPHOSMIN; PROTEIN MDM2; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINO ACID SEQUENCE; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL CULTURE; CELL ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE SYNTHESIS; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; ALLOTRANSPLANTATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KARYOTYPING; MIDDLE AGED; MORTALITY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TUMOR SUPPRESSOR PROTEIN P14ARF; YOUNG ADULT;

EID: 79951590486     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903111914     Document Type: Article

References (28)

1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood 1998;92:2322-2333. (Pubitemid 28452973)
2. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-1320.
3. Bacher U, Haferlach T, Schoch C, et al. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006;107:3847-3853. (Pubitemid 43726786)
4. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-266. (Pubitemid 40110814)
5. Bienz M, Ludwig M, Leibundgut EO, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005;11:1416-1424. (Pubitemid 40315221)
6. Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-448. (Pubitemid 46105936)
7. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998;8:345-357. (Pubitemid 29131356)
8. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994;14:1815-1823. (Pubitemid 24074576)
9. Nahi H, Lehmann S, Bengtzen S, et al. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leuk Lymphoma 2008;49:508-516. (Pubitemid 351298335)
10. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8:282-288. (Pubitemid 34250107)
11. Brooks CL, Gu W. Dynamics in the p53-Mdm2 ubiquitination pathway. Cell Cycle 2004;3:895-899. (Pubitemid 40179468)
12. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-F177. (Pubitemid 28530512)
13. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003;13:77-83. (Pubitemid 36143931)
14. Muller-Tidow C, Metzelder SK, Buerger H, et al. Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia. Leukemia 2004;18:720-726. (Pubitemid 38500189)
15. Sundman-Engberg B, Tidefelt U, Liliemark J, et al. Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo. Cancer Chemother Pharmacol 1990;25:252-256. (Pubitemid 20014967)
16. Sundman-Engberg B, Tidefelt U, Gruber A, et al. Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs. in vivo. Leuk Res 1993;17:347-352. (Pubitemid 23146250)
17. Rhedin AS, Tidefelt U, Jonsson K, et al. Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk Res 1993;17:271-276. (Pubitemid 23092971)
18. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011-4020. (Pubitemid 43726809)
19. Andersson A, Johansson B, Lassen C, et al. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol 2004;72:307-313. (Pubitemid 38520727)
20. Ito A, Lai CH, Zhao X, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001;20:1331-1340. (Pubitemid 32233973)
21. Fenaux P, Preudhomme C, Lai JL, et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 1992;6:246-250.
22. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003;17:1813-1819. (Pubitemid 37185257)
23. Siebert R, Willers CP, Schramm A, et al. Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines. Br J Haematol 1995;91:350-354.
24. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-734. (Pubitemid 28155312)
25. Cheng K, Grisendi S, Clohessy JG, et al. The leukemiaassociated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: arf inactivation and induction of cellular senescence. Oncogene 2007;26:7391-7400. (Pubitemid 350158712)
26. Cory AH, Chen J, Cory JG. Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis. Anticancer Res 2006;26:1289-1295.
27. Nahi H, Merup M, Lehmann S, et al. PRIMA - 1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 2006;132:230-236. (Pubitemid 43381557)
28. Bykov VJ, Issaeva N, Selivanova G, et al. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002;23:2011-2018. (Pubitemid 36104953)